{"entity":{"id":"vs-7375","kind":"drug","name":"VS-7375","aka":[],"tldr":"VS-7375 is an experimental small-molecule drug from Verastem in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.","summary":"VS-7375 is a small-molecule drug developed by Verastem. Its target is KRAS (the sponsor names KRAS G12D). The sponsor states: An oral KRAS G12D (ON/OFF) inhibitor. ClinicalTrials.gov describes the intervention as: VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer. The largest, NCT07020221, plans to enrol 295 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of VS-7375","url":"https://clinicaltrials.gov/search?intr=VS-7375"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","nsclc","colorectal"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["verastem"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07659782","nct07659795","nct07644559","nct07020221"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"An oral KRAS G12D (ON/OFF) inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vs-7375/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"}],"trial":[{"id":"nct07020221","kind":"trial","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","route":"/trials/nct07020221/"},{"id":"nct07659795","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","route":"/trials/nct07659795/"},{"id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct07659782/"},{"id":"nct07644559","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","route":"/trials/nct07644559/"}]}}